To ask Her Majesty's Government what steps they are taking to ensure that there will be an equitable distribution of a COVID-19 vaccine among developing nations, if such a vaccine is developed in the UK.
5 August 2020
As the world grapples with the burden of the COVID-19 pandemic, the UK has been clear that equitable global distribution of a vaccine will be the best defence, enable collective recovery and reduce the risk of repeat outbreaks.
The UK is supporting the COVAX Advance Market Commitment (AMC) which aims to ensure access to COVID-19 vaccines in developing countries. At the Global Vaccine Summit, which the Prime Minister hosted on 4th June, the UK repurposed £48 million to the AMC. At the Summit, AstraZeneca also announced a commitment of 300 million doses of the University of Oxford candidate vaccine to the COVAX facility.
The COVAX AMC will incentivise vaccine manufacturers to produce sufficient quantities of eventual COVID-19 vaccines and to ensure access for the world’s poorest countries. Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations, and the World Health Organization are working together to ensure that the vaccines are affordable and available equitably. Through the deal with AstraZeneca, the University of Oxford COVID-19 vaccine candidate have been committed towards the COVAX Facility.